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Open Forum Infectious Diseases
MAJOR ARTICLE

Comparing the Diagnostic Accuracy of Clinician
Judgment to a Novel Host Response Diagnostic for Acute
Respiratory Illness
1
Duke Center for Applied Genomics & Precision Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA, 2Department of Emergency Medicine, Henry
Ford Hospital, Wayne State University, Detroit, Michigan, USA, 3Department of Emergency Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA, 4Medical
Service, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA, and 5Emergency Medicine Service, Durham Veterans Affairs Health Care System, Durham, North Carolina,
USA

Background. Difficulty discriminating bacterial from viral infections drives antibacterial misuse. Host gene expression tests
discriminate bacterial and viral etiologies, but their clinical utility has not been evaluated.
Methods. Host gene expression and procalcitonin levels were measured in 582 emergency department participants with suspected infection. We also recorded clinician diagnosis and clinician-recommended treatment. These 4 diagnostic strategies were
compared with clinical adjudication as the reference. To estimate the clinical impact of host gene expression, we calculated the
change in overall Net Benefit (∆NB; the difference in Net Benefit comparing 1 diagnostic strategy with a reference) across a range of
prevalence estimates while factoring in the clinical significance of false-positive and -negative errors.
Results. Gene expression correctly classified bacterial, viral, or noninfectious illness in 74.1% of subjects, similar to the other
strategies. Clinical diagnosis and clinician-recommended treatment revealed a bias toward overdiagnosis of bacterial infection resulting in high sensitivity (92.6% and 94.5%, respectively) but poor specificity (67.2% and 58.8%, respectively), resulting in a 33.3%
rate of inappropriate antibacterial use. Gene expression offered a more balanced sensitivity (79.0%) and specificity (80.7%), which
corresponded to a statistically significant improvement in average weighted accuracy (79.9% vs 71.5% for procalcitonin and 76.3%
for clinician-recommended treatment; P < .0001 for both). Consequently, host gene expression had greater Net Benefit in diagnosing
bacterial infection than clinician-recommended treatment (∆NB = 6.4%) and procalcitonin (∆NB = 17.4%).
Conclusions. Host gene expression–based tests to distinguish bacterial and viral infection can facilitate appropriate treatment,
improving patient outcomes and mitigating the antibacterial resistance crisis.
Keywords. bacterial infection; clinical decision-making; gene expression; procalcitonin; diagnostic test.
Acute respiratory illness (ARI) is one of the most common
complaints seen in emergency department (ED) and outpatient
settings but remains difficult to treat accurately [1–4]. Possible
causes of ARI include bacterial infection, viral infection, bacterial/viral co-infection, and noninfectious etiologies, such as
asthma, allergic rhinitis, postinfection cough, and chronic obstructive pulmonary disease (COPD) [5]. Diagnostic uncertainty leads to prolonged ED visits and improper antibiotic use
due to concerns about missing bacterial infection, which has
the unintended consequence of driving antibacterial resistance, worsening health outcomes, and increasing costs [6–11].
Even with recent improvements in antibiotic stewardship, 30%
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of prescribed antibacterials in the United States are considered
inappropriate [12]. Conversely, knowing when to appropriately
give antibacterials and antivirals like oseltamivir is important as
early intervention can significantly reduce morbidity and mortality [13, 14].
In recent years, emerging technologies have made host
response–based diagnostics a viable option to discriminate bacterial, viral, and noninfectious illness [15]. Initially,
procalcitonin was examined as a diagnostic biomarker for
bacterial infections, but multigene transcriptional panels
have proven superior at discriminating bacterial from viral
etiologies and even predicting disease before clinical symptoms [16–21]. We previously discovered a host gene expression signature that differentiates bacterial ARI, viral ARI,
and noninfectious illness with an overall accuracy of 87%
when compared with expert adjudications [22]. This host
response signature has also been developed into a rapid research use–only test (45 minutes) providing accurate discrimination of bacterial and viral etiologies directly from a
blood sample [23].
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Whereas clinical utility is best measured using prospective
clinical trials, a retrospective approach affords a readily available estimate of potential clinical utility. We present evidence
from a large population of ED patients showing that a host
gene expression test can augment current clinical practice to
improve diagnostic accuracy and clinical care. This is the first
such analysis to retrospectively define the potential clinical
impact of a transcriptional biomarker for bacterial/viral discrimination in ARI.

Patient Consent

All studies were approved by relevant institutional review
boards and in accordance with the Declaration of Helsinki. All
subjects or their legally authorized representatives provided
written informed consent.
Study Design

Subjects analyzed in this study derived from a prior publication
evaluating host gene expression measured using quantitative
reverse transcription polymerase chain reaction (qRT-PCR)
on a research use–only BioFire system [23]. That study reported results for 623 participants. However, this study focused
on 582 after excluding those with inadequate medical record
information, fungal infection, or incomplete data. Details regarding enrollment criteria and study sites can be found in the
Supplementary Methods.
Reference Standard

As previously described, expert adjudications served as the
reference standard [23]. Two independent adjudications were
conducted by emergency medicine, infectious disease, pulmonary/critical care, or hospital medicine specialists using
patient charts and additional microbiological test data that
were reviewed retrospectively. This included clinical data
(notes, laboratory testing, subject-reported symptoms, and
radiology, as available) from the enrollment and follow-up
visits [22]. Supplemental etiology testing included the
BinaxNOW S. pneumoniae urinary antigen test (Alere) and
multiplex respiratory pathogen testing (ResPlex V2.0, Qiagen;
Respiratory Viral Panel, Luminex; or Respiratory Pathogen
Panel, Luminex). As such, adjudicators had access to more
information than would be available to clinicians in real
time. Subjects were classified as having a bacterial infection,
viral infection, bacterial–viral co-infection, or a noninfectious process. Disagreements were reconciled by panel review
consisting of at least 3 adjudicators. Subjects adjudicated as
bacterial–viral co-infection were treated as bacterial, as both
would lead to antibacterial therapy [24]. Adjudications were
blind to any host gene expression data and procalcitonin concentrations, which were not available at the enrolling institutions during the study period.
2 • OFID • Jaffe et al

No new gene expression or procalcitonin data were generated
for this analysis. Instead, we relied upon data generated in previously published research. Details regarding measurement of
the host gene expression signature and procalcitonin can be
found in the Supplementary Methods. We used the established
procalcitonin threshold of >0.25 µg/L to denote a bacterial infection [25]. Probabilities for bacterial, viral, and noninfectious
illness using the gene expression test were determined by the
predictive algorithm as previously published [23]. Host gene expression samples were classified as bacterial, viral, co-infection,
or noninfectious illness based on whether the predicted probabilities of bacterial and viral infection exceeded the specified
thresholds [23].
Medical Record Review

Medical records were reviewed to extract the variables listed
in Supplementary Table 1. This included the clinician’s documented diagnosis (bacterial, viral, noninfectious, inconclusive,
or unknown). The clinician-diagnosed etiology was considered
inconclusive if the clinician diagnosis was a symptom (eg,
cough) or included multiple unresolved diagnoses of distinct
etiologies (eg, bacterial pneumonia vs viral upper respiratory
infection). Visit outcome (treated and released, admitted, or deceased), length of hospitalization, and length of intensive care
unit stay were also recorded, if applicable. Clinician treatment
was categorized as antiviral or antibacterial. The same information was collected for any other health care visits 30 days before
and after enrollment.
Statistical Analysis

Statistical analysis was conducted in R, version 3.6 (Foundation
for Statistical Computing, Vienna, Austria). The 4 diagnostic strategies were (1) clinician diagnosis, (2) clinicianrecommended treatment, (3) procalcitonin-defined etiology
(bacterial vs nonbacterial), and (4) host gene expression–
based diagnosis (bacterial, viral, co-infection, or no infection).
These were all compared with the expert panel adjudication
as the reference standard (Figure 1). “Inconclusive” cliniciandiagnosed etiologies (ie, cases in which the clinician only provided a differential diagnosis) were assigned an etiology based
on the clinician-recommended treatment (eg, prescription for
antibacterials would classify the subject as having a bacterial infection diagnosis).
Sensitivity and specificity were calculated using adjudication as the reference standard and compared using McNemar’s
test. Average weighted accuracy (AWA)—a metric of test utility
accounting for the relative importance of sensitivity and specificity in a range of disease prevalence—was calculated for bacterial and viral discrimination as previously described [24]. Based
on a previously reported clinician survey, a relative importance
of 0.25 (indicating that sensitivity is 4 times more important
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Figure 1. Summary of major diagnostic approaches. Blinded expert adjudications were used as the reference standard to compare performance characteristics of 4 strategies. The arrows denote the 4 diagnostic strategies where expert adjudication served as the reference standard. The clinician diagnosis was based on the clinician’s assessment and discharge diagnosis documented in clinical notes. Clinician-recommended treatment was defined as bacterial if antibacterial drugs were prescribed, viral if antiviral
drugs or supportive care was prescribed, or noninfectious if a noninfectious disease process was treated. The host gene expression test results were based on probability
thresholds for bacterial vs nonbacterial infection and viral vs nonviral infection. Procalcitonin concentrations >0.25 μg/L were considered to indicate a bacterial infection.

than specificity) and a prevalence estimate of 10%–30% were
used to compute bacterial AWA [24]. For viral AWA, a relative
importance of 2 (indicating that specificity is twice as important as sensitivity) and a prevalence estimate of 50%–80% were
used. Immunocompetent and immunocompromised subjects
were also compared with respect to overall accuracy, sensitivity, and specificity using Barnard’s exact test. Change in Net
Benefit (∆NB) was calculated as previously described, using the
same relative importance and prevalence estimates as for AWA
[26, 27]. Net Benefit (NB) incorporates a relative weighting of
severity for false negatives and false positives to estimate the
percentage of patients benefiting from using a new diagnostic
as the sole means of diagnosing an illness. NB is defined as
True Positives + True Negatives – (False Negatives × HarmFN)
– (False Positives × HarmFP), where the HarmFN is the harm of
an individual going untreated (Profit/Loss ratio) and HarmFP is
 
 
its reciprocal [27]. In short, NB = TP + TN − FN PL − FP PL
. The ∆NB is the difference in Net Benefit when comparing 1
diagnostic strategy to a reference.
RESULTS
Cohort Characteristics

The study cohort of 582 subjects was 52.4% female, 51.2%
White, 45.0% Black/African American, and 3.8% other selfreported race, with a mean age (range) of 47.5 (14–94) years.
Demographics of subjects grouped by expert-adjudicated etiology are shown in Supplementary Table 2. There were 115
subjects (19.8%) who had additional visits with a health care
provider for the same illness within 30 days of enrollment. A
medical history of lung disease was present in 226 (38.8%)
subjects (most commonly asthma [17.4%] and COPD [11.2%]).
Clinical adjudication assigned 271 (46.6%) subjects as having a
bacterial infection (including 62 bacterial–viral co-infections),

208 (35.7%) with a viral infection, and 103 (17.7%) with a noninfectious illness. Viral infections had the lowest hospital admission rates (20.7%) and shortest mean length of stay (1.1 days).
The majority (60.5%) of subjects admitted with viral etiologies
had a history of noninfectious respiratory illness such as asthma
or COPD and were older than subjects who were treated and
released (mean, 52 vs 40 years; P < .0001). Conversely, subjects
with bacterial infections and noninfectious illness had high
admission rates (69.4% and 66.0%, respectively) and longer
mean lengths of stay (5.8 days and 4.6 days, respectively). Of
the subjects admitted, 6 died during their hospital admission (5
with bacterial etiologies and 1 with a noninfectious etiology).
Diagnostic Performance

Clinician diagnosis, treatment plan, host gene expression, and
procalcitonin were compared with adjudication as the reference standard (Table 1). As adjudicators had access to more
clinical information including supplemental microbiological
testing, results from clinically ordered cultures, and follow-up
assessments, it was felt that adjudicator assignments were more
accurate than clinical diagnoses made in real time. Clinicians
diagnosed 75.4% of subjects with the correct etiology but reduced their diagnostic accuracy to 72.2% as reflected by their
treatment plans. This treatment incongruent with the diagnosis was largely due to clinicians prescribing antibacterials despite diagnosing a viral or noninfectious condition. Clinicians
showed a strong sensitivity bias toward diagnosing and treating
bacterial infections, at the expense of bacterial specificity and
viral sensitivity. Using clinician-recommended treatment as the
source of diagnostic information, clinicians had 94.5% sensitivity (95% CI, 91.0%–96.9%) and 58.8% specificity (95% CI,
53.1%–64.4%) for bacterial etiologies. The converse was true
with respect to viral infection diagnosis: 52.4% sensitivity (95%
CI, 45.4%–59.4%) and 96.3% specificity (95% CI, 93.8%–98.0%).
Comparing Host Response Strategies • OFID • 3
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Clinician diagnosis

Table 1.

Comparison of Diagnostic Test Performance
Overall Accuracy, %

Bacterial Sensitivity, %

Bacterial
Specificity, %

Bacterial
AWA, %

Viral Sensitivity, %

Viral Specificity, %

Viral AWA, %

Host gene expression

74.1

79.0a
(73.6–83.7)

80.7b,c
(75.9–85.0)

79.9a,b
(76.6–83.1)

76.0 b,d
(69.6–81.6)

86.4
(82.5–89.7)

81.3b,c
(77.9–84.6)

Procalcitonin

72.2

56.8
(50.7–62.8)

85.5
(81.1–89.3)

71.5
(68.0–75.0)

Clinician diagnosis

75.4

92.6e
(88.8–95.4)

67.2
(61.7–72.4)

79.7
(76.6–82.7)

60.6
(53.6–67.3)

94.9e
(92.2–96.9)

78.2
(74.7–81.6)

Clinician-recommended treatment

72.2

94.5e
(91.0–96.9)

58.8 (53.1–
64.4)

76.3
(73.2–79.4)

52.4
(45.4–59.4)

96.3e
(93.8–98.0)

74.9
(71.4–78.3)

Test or Approach (n = 582)

Abbreviation: AWA, average weighted accuracy.
a

P < .0001 compared with procalcitonin.

b

P< .0001 compared with clinician-recommended treatment.

c

P < .0001 compared with clinician diagnosis.

d

P < .001 compared with clinician diagnosis.

e

P < .0001 compared with host gene expression.

As a result of this propensity to overdiagnose and overtreat
bacterial infections, clinicians prescribed antibacterials inappropriately to 128 subjects adjudicated as having viral etiologies (22.0% of all subjects and 33.3% of subjects who received
antibiotics).
In contrast, host gene expression had more balanced performance characteristics for the diagnosis of bacterial infection: 79.0% sensitivity (95% CI, 73.6%–83.7%) and 80.7%
specificity (95% CI, 75.9%–85.0%). Sensitivity and specificity
were also more balanced using host gene expression to diagnose viral infections as compared with clinician diagnosis and
treatment: 76.0% sensitivity (95% CI, 69.6%–81.6%) and 86.4%
specificity (95% CI, 82.5%–89.7%). In terms of bacterial AWA,
host gene expression had the best diagnostic performance of
all the approaches, with a bacterial AWA of 79.9% (95% CI,
76.6%–83.1%) compared with clinician diagnosis (79.7%; 95%
CI 76.6%–82.7%; P = .70) and clinician treatment (76.3%; 95%
CI, 73.2%–79.4%; P < .00001). Similar results were seen for
viral illness, with host gene expression having the highest viral
AWA of all the approaches at 81.3% (95% CI, 77.9%–84.6%).
This was significantly better than clinician diagnosis (viral
AWA, 78.2%; 95% CI, 74.7%–81.6%; P < .00001) and clinicianrecommended treatment (viral AWA, 74.9%; 95% CI, 71.4%–
78.3%; P < .00001).
Meanwhile, procalcitonin performed worse than all other diagnostic approaches on every measure. Notably, procalcitonin
had the lowest bacterial sensitivity of all the assays, 56.8% (95%
CI, 50.7%–62.8%), with a corresponding specificity of 85.5%
(95% CI, 81.1%–89.3%), both significantly worse than host gene
expression (P < .0001). The AWA for bacterial infection was
71.5% (95% CI, 68.0%–75.0%), which was significantly worse
than clinician diagnosis, clinician-recommended treatment, and
host gene expression (P < .00001 for all 3. Overall, of the 4 diagnostic approaches (clinician diagnosis, clinician-recommended
treatment, host gene expression, and procalcitonin), host gene
4 • OFID • Jaffe et al

expression had the highest AWA for discriminating viral and
bacterial infections.
We then evaluated these diagnostic strategies in subjects with
(n = 57) or without (n = 525) immunocompromising conditions
(Table 2). The overall accuracies were similar for the 2 groups
using both host gene expression and procalcitonin. Although
accuracies were lower among immunocompromised subjects
using clinician diagnosis (64.9% vs 76.6%) and clinicianrecommended treatment (64.9% vs 73.0%), the difference was
not statistically significant. Differences were also observed for
sensitivity and specificity, which in some cases were statistically
significant, as noted in Table 2.
Change in Net Benefit

In order to estimate the clinical impact of host response strategies, we calculated the change in overall Net Benefit (∆NB).
At a basic level, this value represents the percentage of patients
who would benefit from a new diagnostic strategy as compared with current practice. For classifying bacterial etiologies,
the base case scenario assumed a 20% prevalence of bacterial
etiologies and a relative importance value (r) of 0.25 based on
the same assumptions made when calculating AWA. In this
scenario, host gene expression provided an improvement over
clinician-recommended treatment with a ∆NB of 6.4%. In this
scenario, host gene expression also provided an overall Net
Benefit improvement over procalcitonin (∆NB = 17.4%). With
respect to viral ARI, the base case assumed a viral prevalence of
65% and an r value of 2. Host gene expression showed an improvement over clinician-recommended treatment with a ∆NB
12.6%. We did not calculate a ∆NB for procalcitonin pertaining
to viral infection as procalcitonin is unable to differentiate viral
from noninfectious illness.
We performed sensitivity analyses to evaluate the impact
of prevalence as well as relative importance, r, on ∆NB for
the 3 main comparisons (bacterial ∆NB of gene expression vs
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All values are shown with 95% CIs.

Table 2.

Comparison of Diagnostic Performance in Immunocompromised and Immunocompetent Subjects

Approach

Bacterial
Sensitivity, %

Bacterial
Specificity, %

Bacterial
AWA, %

Viral Sensitivity, %

Viral Specificity, %

Host gene expression

Viral AWA, %

Immunocompetent (n
= 525)

74.5

78.0
(72.2–83.0)

81.8
(76.8–86.1)

79.9
(76.4–83.3)

76.9
(70.4–82.6)

85.8
(81.5–89.3)

81.4
(78.0–84.9)

Immunocompromised
(n = 57)

70.2

88.5
(69.9–97.6)

71.0
(52.0–85.8)

79.5
69.4–89.7)

61.5
(31.6–86.1)

90.9
(78.3–97.5)

76.6 (
63.0–90.2)

Procalcitonin

Immunocompetent (n
= 525)

72.4

55.9
(49.5–62.2)

86.8
(82.3–90.5)

71.7
(68.0–75.3)

Immunocompromised
(n = 57)

70.2

65.4
(44.3–82.8)

74.2
(55.4–88.1)

69.9
(58.0–81.8)

Clinician diagnosis

Immunocompetent (n
= 525)

76.6

92.7
(88.6–95.6)

69.3a
(63.5–74.6)

80.7
(77.5–83.9)

63.1a
(55.9–69.9)

94.9
(91.9–97.0)

79.4
(75.8–82.9)

Immunocompromised
(n = 57)

64.9

92.3
(74.9–99.1)

48.4
(30.2–66.9)

69.9
59.6–80.2)

23.1
(5.0–53.8)

95.5 (
84.5–99.4)

60.2
(48.6–71.8)

Clinician-recommended
treatment

Immunocompetent (n
= 525)

73.0

94.3
(90.6–96.8)

60.7a
(54.7–66.5)

77.2
(73.9–80.4)

54.4 (4
7.1–61.5)

98.4
(93.7–98.1)

75.9
(72.3–79.4)

Immunocompromised
(n = 57)

64.9

96.2
(80.4–99.9)

41.9
(24.6–60.9)

68.5
(58.9–78.1)

23.1
(5.0–53.8)

95.5
(84.5–99.4)

60.2
(48.6–71.8)

All values are shown with 95% CIs.
Abbreviation: AWA, average weighted accuracy.
a

P < .05 between immunocompetent and immunocompromised groups after comparing all test metrics between groups.

clinician-recommended treatment, bacterial ∆NB of gene expression vs procalcitonin, and viral ∆NB of gene expression vs
clinician-recommended treatment) (Figures 2 and 3). In general,
host gene expression ∆NB increases when the prevalence of
bacterial infections declines or when viral infection prevalence
rises. Examining the impact of relative importance, r, we found
that host gene expression provided a greater Net Benefit than
did procalcitonin at all values of r. However, if r decreased to
0.125 (willing to accept 8 false-positive bacterial diagnoses to
avoid 1 false-negative), then gene expression would no longer
provide a Net Benefit over clinician-recommended treatment

Change in overall net benefit

A

B

Clinician diagnosis

0.0%

Impact of Diagnostic Errors

Inappropriate treatment (both under- and overtreatment)
could result in repeated visits for clinical worsening or treatment complications. We therefore examined the impact of diagnostic errors and whether alternative diagnostic testing could
have averted them. There were 115 subjects (19.8%) who had
ARI-related visits within 30 days before or after enrollment. For

Clinician-recommended treatment

0.4

0.4

plans. In this scenario, the perceived harm of antibiotic overuse
was considered less impactful than the harm of undertreating a
bacterial infection.

C
0.4

6.4%

17.4%

0.2

0.2

0.0

0.0

0.0

–0.2

Prevalence –0.2
10%
20% –0.4
30%

Prevalence –0.2
10%
20% –0.4
30%

0.2

–0.4
0.0

0.2
0.4
0.6
0.8
Relative importance (r)

1.0

False negatives more serious than false positives

0.0

Procalcitonin

0.6
0.8
0.2
0.4
Relative importance (r)

1.0

False negatives more serious than false positives

Prevalence
10%
20%
30%
0.0

0.6
0.8
0.2
0.4
Relative importance (r)

1.0

False negatives more serious than false positives

Figure 2. Change in overall Net Benefit (∆NB) for bacterial infection. This figure shows change in overall Net Benefit curves for diagnosis of bacterial vs nonbacterial
etiologies. As relative importance (r) decreases, there is a greater emphasis on avoiding false-negative bacterial diagnoses (failing to diagnose a bacterial infection when
one is present) at the expense of false-positive bacterial diagnoses (diagnosing a bacterial infection when none is present). The base case assumes an r value of 0.25
(vertical red dashed line) and a bacterial prevalence of 20% (solid blue line) with +/-10% margins. A positive ∆NB indicates that the host gene expression test provides a
net clinical benefit over the comparator diagnostic strategy. A, Comparison of host gene expression with clinician diagnosis. B, Comparison of host gene expression with
clinician-recommended treatment. C, Comparison of host gene expression with procalcitonin.
Comparing Host Response Strategies • OFID • 5
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Overall Accuracy, %

Immune Status

B

Clinician diagnosis
0.4

0.4

0.2

0.2

Clinician-recommended treatment

12.6%
6.1%

0.0

0.0
–0.2

–0.2

Prevalence
50%
65%
80%

–0.4
0

1

2
3
4
5
Relative importance (r)

Prevalence
50%
65%
80%

–0.4
6

False positives more serious than false negatives

0

1

2
3
4
5
Relative importance (r)

6

False positives more serious than false negatives

Figure 3. Viral change in overall Net Benefit (∆NB) curves. This figure shows change in overall Net Benefit curves for diagnosis of viral vs nonviral etiologies. As relative
importance (r) increases, there is a greater emphasis on avoiding false positives (diagnosing a viral infection when none is present) at the expense of false negatives (failing
to diagnose a viral infection when one is present). The base case assumes an r value of 2 (vertical red dashed line) and a viral prevalence of 65% (solid purple line) with
+/-15% margins. A positive ∆NB indicates that the host gene expression test provides a net clinical benefit over the comparator diagnostic strategy. A, Comparison of host
gene expression with clinician diagnosis. B, Comparison of host gene expression with clinician-recommended treatment. A comparison with procalcitonin is not feasible as
this biomarker does not discriminate viral from noninfectious etiologies.

31 subjects, the physician diagnosis changed with subsequent
visits. In 15 of these cases, a bacterial infection was initially
missed. Ten of these subjects were hospitalized due to delays in
initiation of antibacterial therapy. The host gene expression test
would have identified 9 as bacterial, highlighting an opportunity to start appropriate antibacterial therapy more quickly in
those who need it. The 84 cases in which the diagnosis was unchanged through 30 days of follow-up were distributed among
all 3 adjudicated etiologies (n = 32 bacterial/coinfection, n = 34
viral, and n = 18 noninfectious illness) and were largely characterized by return visits for persistent symptoms.
In addition to assessing the impact of missed bacterial infections, we examined inappropriate antibacterial prescription rates. In our cohort, 128 subjects adjudicated as having
a nonbacterial illness were prescribed antibacterial drugs, resulting in a 33.3% rate of inappropriate prescribing. A hypothetical strategy in which host gene expression was the sole
determinant of antibacterial therapy would have decreased inappropriate antibacterial administration to 21.7% of antibacterials
prescribed, slightly better than procalcitonin algorithms, which
would have reduced it to 22.6%.
DISCUSSION

Antimicrobial resistance poses a global threat that has worsened over time. There are many strategies aimed at combatting this problem. Among them is the more prudent use of
antimicrobials so as to reduce the selective pressures driving resistance. ARI is the most frequent reason for infectious disease–
related acute care visits and the most common condition in
6 • OFID • Jaffe et al

which antibacterials are inappropriately prescribed, especially
as diagnostic testing remains unavailable in many outpatient
settings. Therefore, easy and rapid diagnostics to guide appropriate antibiotic use are paramount. Specifically, tests to differentiate viral and bacterial infections can play an important role
in improving individual patient care as well as public health.
Host response–based diagnostics are particularly compelling
as the immune response differentiates bacterial and viral disease. New and emerging host response strategies have thus far
focused on differentiating bacterial from viral infection as the
primary end point [23, 28–31]. However, this is only useful if it
translates into clinical action. Procalcitonin has demonstrated
mixed results regarding the ability to limit unnecessary antibiotic use, demonstrating that clinical utility is paramount [32,
33]. In this study, we model the potential clinical utility of a host
gene expression test that discriminates bacterial from viral infection as compared with current clinical decision-making and
procalcitonin. We show that current practice is heavily weighted
to overtreat with antibacterials and that host gene expression
can mitigate this practice even more so than procalcitonin.
The overall accuracy of the host gene expression–based test
provides an indication that the current iteration of the host
gene expression diagnostic can perform well in a clinical setting. And the relatively well-balanced sensitivity and specificity
of host gene expression provides evidence that this performance is relatively unbiased, especially when compared with
clinicians—who have a sizeable sensitivity bias toward finding
bacterial infections, to the detriment of specificity in identifying
these infections. This sensitivity bias is likely driven by a desire
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Change in overall net benefit

A

that host gene expression testing should be used instead of
procalcitonin to improve the initial treatment of ARI, which is
likely to improve patient outcomes and health care costs, while
avoiding unnecessary antibacterial usage.
It is important to note that the distribution of disease etiology seen in this sample is not representative of the actual
distribution within the population [15]. Rather, samples were
selected to have a roughly equal distribution of etiologies for
the purposes of the initial biosignature development. Bacterial
infections were overrepresented while viral etiologies were
underrepresented in this study compared with actual disease
prevalence [15]. As a result of this skewed distribution and the
disparate clinical impacts of bacterial, viral, and noninfectious
etiologies, standard measures of diagnostic performance (accuracy, sensitivity, specificity, etc.) are inadequate for estimating
the potential diagnostic value of different methodologies. Thus,
AWA and ∆NB (which correct for these issues) were utilized in
our analyses to account for these limitations.
While this study was inherently limited by its retrospective
nature, we showed that this host gene expression diagnostic
has the potential to significantly improve the clinical diagnosis
of acute respiratory illness etiologies, potentially guiding more
accurate clinical interventions. We note that our findings reflect an idealized scenario and did not account for the complexities motivating clinicians to prescribe antibacterials (eg,
patient requests, patient satisfaction scores, time pressures,
etc.). This improved diagnostic accuracy can reduce antibacterial misuse, averting financial and health costs, while also
averting missed diagnoses of potentially critical infections.
However, the behavior of clinicians in the context of a novel
diagnostic cannot be retrospectively assessed, especially in the
context of a growing emphasis on antibacterial stewardship.
Thus, confirmation of these findings with prospective testing,
including the use of stewardship programs and a more heterogeneous patient population, is necessary to demonstrate
clinical utility and support the adoption of novel host-based
diagnostics.
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